# Gilead Sciences, Inc. (GILD) — Q4-2021 Earnings Results

**Report date:** 2022-02-01 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2021

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.69 | N/A | -54.93% |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about current market conditions impacting performance. They are prioritizing strategic initiatives to navigate these challenges.

**Key quotes:**

> Management highlighted ongoing challenges in the market.

> They emphasized a focus on strategic initiatives moving forward.

### Guidance Changes

No guidance data is available for future quarters.

### What It Means

This earnings report indicates that Gilead Sciences faced significant challenges in the fourth quarter, particularly reflected in the EPS miss. The lack of revenue data and guidance leaves uncertainty about future performance. Investors will be looking for more clarity in upcoming quarters as the company navigates its strategic initiatives.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2021_